The duration of resistance to crizotinib for ROS1 mutation in lung cancer is about 11 months and varies somewhat from person to person. The drug needs to be used under the guidance of a doctor. Crizotinib is the drug of choice for the treatment of lung adenocarcinoma, and patients with ROS1 mutation in lung cancer can be treated with crizotinib, which can improve the patient’s treatment effect, prolong the patient’s life, and reduce the risk of recurrence and metastasis. However, even patients who are sensitive to the drug will eventually develop resistance to it, with most patients developing resistance around November. This drug may cause side effects on the skin, kidneys, liver and heart after taking it. It is recommended that after taking this drug, patients must do regular checkups to detect the side effects early and treat them as early as possible, so as to have a better therapeutic effect, and after the treatment, it should also be judged according to the changes in the condition, and if resistance occurs, the treatment plan needs to be changed immediately.